The Impact of Diagnostic Criteria for Gestational Diabetes Mellitus on Adverse Maternal Outcomes: A Systematic Review and Meta-Analysis
Open accessThe DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.
Abstract
This systematic review and meta-analysis aimed to examine the impact of different gestational-diabetes (GDM) diagnostic-criteria on the risk of adverse-maternal-outcomes. The search process encompassed PubMed (Medline), Scopus, and Web of Science databases to retrieve original, population-based studies with the universal GDM screening approach, published in English language and with a focus on adverse-maternal-outcomes up to January 2020. According to GDM diagnostic criteria, the studies were classified into seven groups. A total of 49 population-based studies consisting of 1409018 pregnant women with GDM and 7,667,546 non-GDM counterparts were selected for data analysis and knowledge synthesis. Accordingly, the risk of adverse-maternal-outcomes including primary-cesarean, induction of labor, maternal-hemorrhage, and pregnancy-related-hypertension, overall, regardless of GDM diagnostic-criteria and in all diagnostic-criteria subgroups were significantly higher than non-GDM counterparts. However, in meta-regression, the increased risk was not influenced by the GDM diagnostic-classification and the magnitude of the risks among patients, using the IADPSG criteria-classification as the most strict-criteria, was similar to other criteria. In conclusion, a reduction in the diagnostic-threshold increased the prevalence of GDM, but the risk of adverse-maternal-outcome was not different among those women who were diagnosed through more or less intensive strategies. Our review findings can empower health-care-providers to select the most cost-effective approach for the screening of GDM among pregnant women.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A global consensus has not been reached about the diagnostic criteria for HDP and GDM, making it challenging to assess differences in their disease burden between countries and areas.”
From A global view of hypertensive disorders and diabetes mellitus during pregnancy (2022) · cites this paper as [28]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Currently, the screening and diagnostic approaches for GDM are under debate24–32 given differences in the focus of different guidelines.”
From A global view of hypertensive disorders and diabetes mellitus during pregnancy (2022) · cites this paper as [28]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
Sterne, J. A., Hernán, M. A., Reeves, B. C., Savović, J., Berkman, N. D., Viswanathan, M., Henry, D., Altman, D. G., Ansari, M. T., Boutron, I., et al. (2016) · BMJ · doi:10.1136/bmj.i4919 · Cited by 20,329 · cited 1×
“The (ROBINS) tool in non-randomized studies of interventions and observational studies was used for assessing the risk of bias [18], which has been recommended by the Cochrane [19].”
MethodStang, A. (2010) · European Journal of Epidemiology · doi:10.1007/s10654-010-9491-z · Cited by 17,396 · cited 1×
“For quality appraisal, the modified Newcastle-Ottawa Quality Assessment Scale was used [17].”
MethodPreferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2010) · International Journal of Surgery · doi:10.1016/j.ijsu.2010.02.007 · Cited by 12,156
International Association of Diabetes and Pregnancy Study Groups Consensus Panel (2010) · Diabetes Care · doi:10.2337/dc09-1848 · Cited by 5,390
2. Classification and Diagnosis of Diabetes: Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s002 · Cited by 3,187
The Pathophysiology of Gestational Diabetes Mellitus
Plows, J. F., Stanley, J. L., Baker, P. N., Reynolds, C. M., & Vickers, M. H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113342 · Cited by 1,874 · cited 1×
“Chronic disturbances in maternal β-cell, release of diabetogenic peptides from the placenta, and hormones may play a key role in the pathophysiology of GDM [5].”
BackgroundHoffman, L., Nolan, C., Wilson, J. D., Oats, J. J. N., & Simmons, D. (1998) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1998.tb140192.x · Cited by 570
Hyperglycemia and Adverse Pregnancy Outcomes
Metzger, B. E., Lowe, L. P., Dyer, A. R., Trimble, E. R., Chaovarindr, U., Coustan, D. R., Hadden, D. R., McCance, D. R., Hod, M., McIntyre, H. D., et al. (2009) · Obstetric Anesthesia Digest · doi:10.1097/01.aoa.0000344706.95925.dc · Cited by 479
Gestational diabetes mellitus: prevalence, risk factors, maternal and infant outcomes
Xiong, X., Saunders, L. D., Wang, F. L., & Demianczuk, N. N. (2001) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(01)00496-9 · Cited by 399 · cited 1×
“…20.6 vs. 22.3 vs. 16.6 Soliman et al., 2018 Qatar IADPSG n = 3027 n = 8995 Hypertensive disorders: 5.5 vs. 3.5; Labor induction: 26.5 vs. 12.4 Xiong et al., 2001 Canada CDA n = 2755 n = 8995 Gestational hypertension: 11.4 vs. 4.8; Pre-eclampsia: 1.1 vs. 1.1 Oster et al., 2014 Canada CDA n =…”
InfluentialWeissgerber, T. L., & Mudd, L. M. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0579-4 · Cited by 357
Naylor, C. D. (1996) · JAMA · doi:10.1001/jama.1996.03530390031030 · Cited by 343 · cited 1×
“Fetal size and macrosomia given fetal insulin response to the elevated glucose level in the body of pregnant women or overtreatment may be associated with an elevated prevalence of cesarean section [7,86].”
BackgroundBehboudi-Gandevani, S., Amiri, M., Bidhendi Yarandi, R., & Ramezani Tehrani, F. (2019) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-019-0406-1 · Cited by 321
Self-citationHedderson, M. (2003) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(03)00661-6 · Cited by 264 · cited 2×
“It should be noted that 9 studies used more than one GDM classification [21,29,40,44, 47,51,53,59,64] as follows: 4 studies used classifications 1 and 5 [40,47,52,63], one used 1 and 2 classifications [59], one used classifications 1, 2 and 4 [51], one used classifications 1 and 7 [21], one used classifications 5 and…”
BackgroundMethodInfluentialRisk factors for gestational diabetes: An umbrella review of meta-analyses of observational studies
Giannakou, K., Evangelou, E., Yiallouros, P., Christophi, C. A., Middleton, N., Papatheodorou, E., & Papatheodorou, S. I. (2019) · PLOS ONE · doi:10.1371/journal.pone.0215372 · Cited by 196
Shand, A. W., Bell, J. C., McElduff, A., Morris, J., & Roberts, C. L. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02431.x · Cited by 168 · cited 2×
“9% studies were prospective or retrospective cohorts [22–68] and 4% were cross-sectional studies [20,21].”
BackgroundInfluentialBlack, M. H., Sacks, D. A., Xiang, A. H., & Lawrence, J. M. (2010) · Diabetes Care · doi:10.2337/dc10-1445 · Cited by 160 · cited 1×
“…vs. Insulin-treated Preeclampsia: 5.1 vs. 8.2 vs. 8.6; Placenta previa: 0.4 vs. 0.5 vs. 0.1; Late pregnancy bleeding: 1.3 vs. 1.3 vs. 1.4 Black et al., 2010 California IADPSG single isolated impaired glucose tolerance (i-IGT1) n =391, Age: 32.1 (5.4), BMI: 28.1 (5.6) isolated impaired…”
InfluentialA population-based study of maternal and perinatal outcome in patients with gestational diabetes
Jacobson, J. D., & Cousins, L. M. (1989) · American Journal of Obstetrics and Gynecology · doi:10.1016/0002-9378(89)90767-9 · Cited by 155
Diagnosis of gestational diabetes mellitus: falling through the net
Meek, C. L., Lewis, H. B., Patient, C. J., Murphy, H. R., & Simmons, D. S. (2015) · Diabetologia · doi:10.1007/s00125-015-3647-z · Cited by 132 · cited 2×
“It should be noted that 9 studies used more than one GDM classification [21,29,40,44, 47,51,53,59,64] as follows: 4 studies used classifications 1 and 5 [40,47,52,63], one used 1 and 2 classifications [59], one used classifications 1, 2 and 4 [51], one used classifications 1 and 7 [21], one used classifications 5 and…”
MethodInfluentialGestational diabetes screening with the new IADPSG guidelines: a cost-effectiveness analysis
Mission, J. F., Ohno, M. S., Cheng, Y. W., & Caughey, A. B. (2012) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2012.06.048 · Cited by 129 · cited 1×
“Until now, there are not sufficient data to demonstrate the cost-effectiveness superiority of one screening and diagnostic approach over the other [75,76].”
BackgroundKaul, P., Savu, A., Nerenberg, K. A., Donovan, L., Chik, C. L., Ryan, E. A., & Johnson, J. A. (2014) · Diabetic Medicine · doi:10.1111/dme.12635 · Cited by 118
Bogdanet, D., O’Shea, P., Lyons, C., Shafat, A., & Dunne, F. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9113451 · Cited by 117
Gestational diabetes mellitus: A risk factor for non‐elective cesarean section
Gorgal, R., Gonçalves, E., Barros, M., Namora, G., Magalhães, Â., Rodrigues, T., & Montenegro, N. (2012) · Journal of Obstetrics and Gynaecology Research · doi:10.1111/j.1447-0756.2011.01659.x · Cited by 116
Waters, T. P., Dyer, A. R., Scholtens, D. M., Dooley, S. L., Herer, E., Lowe, L. P., Oats, J. J. N., Persson, B., Sacks, D. A., Metzger, B. E., et al. (2016) · Diabetes Care · doi:10.2337/dc16-1194 · Cited by 111 · cited 1×
“Moses et al., 1995 Australia ADIPS n = 138, Age: 29.5 (5.3) n = 144, Age: 28.2 (5.4) PIH:13.8 vs. 13.2; Labor induction: 26.8 vs. 26.4 Waters et al., 2016 North Ameri- can (1) IADPSG (2) CC (1) n = 878, Age: 31.0 (5.6), BMI: 31.5 (6.4) (2) n = 261, Age: 32.3 (5.3), BMI: 31.6 (5.8) n = 5020, Age:…”
InfluentialWahabi, H., Fayed, A., Esmaeil, S., Mamdouh, H., & Kotb, R. (2017) · BioMed Research International · doi:10.1155/2017/6878263 · Cited by 108 · cited 1×
“…2013 Ireland IADPSG n = 622, Age: 32.8 n = 4225, Age: 31 (4.9) GDM without risk factor vs. GDM with risk factor vs. Non-GDMHypertension: 13 vs. 15 vs. 7 Wahabi et al., 2017 SaudiArabia WHO-2013 n = 2354, Age: 31.5 (5.9) n = 6951, Age: 29.5 (5.7) Gestational hypertension: 1.8 vs.…”
InfluentialAvalos, G., Owens, L. A., Dunne, F., & Collaborators, F. T. A. D. (2013) · Diabetes Care · doi:10.2337/dc12-2669 · Cited by 107 · cited 1×
“…Labor induction: 32.7 vs. 23.9 Anderberg et al., 2010 Sweden WHO-1999 n = 306, Age: 32 (18–46) n = 329, Age: 31 (20–42) Labor induction: 18.6 vs. 6.4 Avalos et al., 2013 Ireland IADPSG n = 622, Age: 32.8 n = 4225, Age: 31 (4.9) GDM without risk factor vs. GDM with risk factor vs.…”
InfluentialQuality of Life in Women with Gestational Diabetes Mellitus: A Systematic Review
Marchetti, D., Carrozzino, D., Fraticelli, F., Fulcheri, M., & Vitacolonna, E. (2017) · Journal of Diabetes Research · doi:10.1155/2017/7058082 · Cited by 100
Moss, J. R., Crowther, C. A., Hiller, J. E., Willson, K. J., Robinson, J. S., & The Australian Carbohydrate Intolerance Study in Pregnant Women (ACHOIS) Trial Group (2007) · BMC Pregnancy and Childbirth · doi:10.1186/1471-2393-7-27 · Cited by 97
Leybovitz-Haleluya, N., Wainstock, T., Landau, D., & Sheiner, E. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1176-1 · Cited by 95 · cited 1×
“…n = 139, Age: 29.6 (5.2), PregnancyBMI: 25.4 (5.3) n = 2583, Age: 27.1 (4.9), Pregnancy BMI: 23.1 (4.5) Weight gain, kg: 9.1 (4.8) vs. 12.9 (5.0) Leybovitz-Haleluya et al., 2018 Israel ACOG GDM A1: n = 9460, Age: 32.1 (5.8) GDM A2: n = 724, Age: 33.7 (5.6) n = 206,013, Age: 28 (5.7) GDM A1…”
InfluentialBrand, J. S., West, J., Tuffnell, D. J., Bird, P. K., Wright, J., Tilling, K. M., & Lawlor, D. A. (2018) · BMC Medicine · doi:10.1186/s12916-018-1191-7 · Cited by 85 · cited 2×
“…GDMDiagnostic Criteria GDM Characteristics * Non-GDM Characteristics * Adverse Maternal Outcome in Women with vs. without GDM, % or Mean (SD) Brand et al.2018 UK Modified WHO-1999 White European: n = 210, Age: 30.2 (5.4), BMI: 28.6 (6.3) South Asian: n = 622, Age: 30.7 (5.3), BMI: 28.2…”
BackgroundInfluentialSacks, D. A., Black, M. H., Li, X., Montoro, M. N., & Lawrence, J. M. (2015) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000000865 · Cited by 75 · cited 1×
“…GDMDiagnostic Criteria GDM Characteristics * Non-GDM Characteristics * Adverse Maternal Outcome in Women with vs. without GDM, % or Mean (SD) Sacks et al., 2015 California IADPSG (1) GDM-1: n = 771, Age: 30.9 (5.6)(2) GDM-2: n = 1121, Age: 31 (5.7) n = 7943, Age: 26.3 (0.1) GDM-1 vs. GDM-2…”
InfluentialVitagliano, A., Saccone, G., Cosmi, E., Visentin, S., Dessole, F., Ambrosini, G., & Berghella, V. (2019) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-018-5005-0 · Cited by 74 · cited 2×
“In addition, inositol as a nutritional supplementation has been shown to improve glycemic homeostasis during pregnancy and prevent GDM [9,10].”
BackgroundRisks of Gestational Diabetes and Preeclampsia Over the Last Decade in a Cohort of Alberta Women
Nerenberg, K. A., Johnson, J. A., Leung, B., Savu, A., Ryan, E. A., Chik, C. L., & Kaul, P. (2013) · Journal of Obstetrics and Gynaecology Canada · doi:10.1016/s1701-2163(15)30786-6 · Cited by 74 · cited 1×
“…(3.4) (2) n = 51, Age: 32.8 (4.3), BMI: 26.5 (4.3) n = 281, Age: 30 (4.7), BMI: 25.5 (3.3) (1) preeclampsia: 18 vs. 17(2) preeclampsia: 28 vs. 17 Nerenberg et al., 2013 Canada CDA n = 15,404, Age: 31.5 (5.4) n = 407,268, Age: 28.4 (5.6) Preeclampsia/eclampsia: 2.6 vs. 1.2; Labor induction:…”
InfluentialTreating mild gestational diabetes mellitus: a cost-effectiveness analysis
Ohno, M. S., Sparks, T. N., Cheng, Y. W., & Caughey, A. B. (2011) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2011.06.051 · Cited by 67
Naylor, C. D. (1996) · JAMA · doi:10.1001/jama.275.15.1165 · Cited by 67
Facchinetti, F., Appetecchia, M., Aragona, C., Bevilacqua, A., Bezerra Espinola, M. S., Bizzarri, M., D’Anna, R., Dewailly, D., Diamanti-Kandarakis, E., Hernández Marín, I., et al. (2020) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2020.1737675 · Cited by 63 · cited 1×
“In addition, inositol as a nutritional supplementation has been shown to improve glycemic homeostasis during pregnancy and prevent GDM [9,10].”
BackgroundMetcalfe, A., Sabr, Y., Hutcheon, J. A., Donovan, L., Lyons, J., Burrows, J., & Joseph, K. S. (2017) · Journal of the Endocrine Society · doi:10.1210/js.2017-00376 · Cited by 63 · cited 1×
“…kg: 12.53 (3.94) vs. 13.76 (3.93) Overweight weight gain, kg: 10.92 (4.49) vs. 12.29 (4.48) Obese weight gain, kg: 8.87 (4.38) vs. 10.50 (4.35) Metcalfe et al., 2017 Canada ICD-10 n = 149,780 n = 2,688,231 Gestational hypertension: 7.93 vs. 4; Mild/unspecified Preeclampsia: 0.32 vs. 0.1;…”
InfluentialChanges in diabetes status between pregnancies and impact on subsequent newborn outcomes
Boghossian, N. S., Yeung, E. H., Albert, P. S., Mendola, P., Laughon, S. K., Hinkle, S. N., & Zhang, C. (2013) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2013.12.026 · Cited by 62 · cited 1×
“…2406, Age: 31.4, BMI: 26 (1) Pre-eclampsia: 10.1 vs. 7.2; PPH:1 vs. 2; APH: 1.6 vs. 2.4 (2) Pre-eclampsia: 9.2 vs. 7.2; PPH:0.4 vs. 2; APH: 2.7 vs. 2.4 Boghossian et al., 2014 USA ICD-9 n = 1279, Age: 30.3 (4.9);Prepregnancy BMI: 28.9 (7.2) n = 58,224, Age: 28.1 (4.5), Prepregnancy BMI: 24.9…”
InfluentialDiabetes in pregnancy among First Nations women in Alberta, Canada: a retrospective analysis
Oster, R. T., King, M., Morrish, D. W., Mayan, M. J., & Toth, E. L. (2014) · BMC Pregnancy and Childbirth · doi:10.1186/1471-2393-14-136 · Cited by 59 · cited 1×
“…Labor induction: 26.5 vs. 12.4 Xiong et al., 2001 Canada CDA n = 2755 n = 8995 Gestational hypertension: 11.4 vs. 4.8; Pre-eclampsia: 1.1 vs. 1.1 Oster et al., 2014 Canada CDA n = 1224, Age: 28.8 (6.27) n = 26,793, Age: 24.7 (5.8) Pregnancy induced hypertension: 11.3 vs. 4.4; Labor…”
InfluentialKawakita, T., Bowers, K. A., Hazrati, S., Zhang, C., Grewal, J., Chen, Z., Sun, L., & Grantz, K. L. (2017) · American Journal of Perinatology · doi:10.1055/s-0037-1604414 · Cited by 59 · cited 1×
“…n = 58,224, Age: 28.1 (4.5), Prepregnancy BMI: 24.9 (5.6) Gestational hypertension: 4.7 vs. 2.2; Preeclampsia: 3 vs. 1.6; Labor induction: 40.2 vs. 39.4 Kawakita et al., 2017 USA ICD-9 n = 11,327, Age: 30.8 (6.0), BMI: 34.1(7.5) n= 208,355, Age: 27.4 (6.1), BMI: 30.6 (6.1) Pregnancy-associated…”
InfluentialCost-effectiveness of controlling gestational diabetes mellitus: a systematic review
Fitria, N., van Asselt, A. D. I., & Postma, M. J. (2019) · The European Journal of Health Economics · doi:10.1007/s10198-018-1006-y · Cited by 58
van Hoorn, J., Dekker, G., & Jeffries, B. (2002) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/j.0004-8666.2002.00035.x · Cited by 55 · cited 1×
“…5.2 (4.5, 5.9) Zeki et al., 2018 Australia ADIPS n = 51135, Age: 32.2 (5.3) n = 950 678, Age: 29.9 (5.6) Primary Cesarean: Relative % 13.8 vs. 13.5 Hoorn et al., 2002 Australia ADIPS n = 51, Age: 30.9 (5.7), BMI:31.5 (.1) n = 258, Age: 24.9 (6.3), BMI: 25.5 (5.9) Gestational hypertension: 45.1…”
InfluentialSu, W., Chen, Y.-L., Huang, P., Shi, X., Yan, F., Chen, Z., Yan, B., Song, H., Lin, M., & Li, X. (2019) · Annals of Nutrition and Metabolism · doi:10.1159/000501710 · Cited by 55
Gestational Diabetes or Lesser Degrees of Glucose Intolerance and Risk of Preeclampsia
Carr, D. B., Newton, K. M., Utzschneider, K. M., Faulenbach, M. V., Kahn, S. E., Easterling, T. R., & Heckbert, S. R. (2011) · Hypertension in Pregnancy · doi:10.3109/10641950903115012 · Cited by 52
Gortazar, L., Flores‐Le Roux, J. A., Benaiges, D., Sarsanedas, E., Payà, A., Mañé, L., Pedro‐Botet, J., & Goday, A. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3151 · Cited by 48
Sletner, L., Jenum, A. K., Yajnik, C. S., Mørkrid, K., Nakstad, B., Rognerud-Jensen, O. H., Birkeland, K. I., & Vangen, S. (2017) · PLOS ONE · doi:10.1371/journal.pone.0172946 · Cited by 47 · cited 1×
“Non-Hispanic Black Gestational weight gain (kg): 11.5 (8.3) vs. 11.1 (8.0) Sletner et al., 2017 Norway WHO-1999 Europe Mild: n = 30, Age: 31.2 (29.5), BMI: 25.5 (23.8, 27.2) Moderate/severe: n = 9, Age: 30.6 (27.6, 33.5), BMI: 30.5 (27.4, 33.6) South Asia Mild: n = 9, Age: 30.7 (28.3, 33.0), BMI:…”
InfluentialGestational diabetes mellitus and quality of life during the third trimester of pregnancy
Pantzartzis, K. A., Manolopoulos, P. P., Paschou, S. Α., Kazakos, K., Kotsa, K., & Goulis, D. G. (2019) · Quality of Life Research · doi:10.1007/s11136-018-2090-2 · Cited by 47
Decreased perinatal mortality among women with diet‐controlled gestational diabetes mellitus
Karmon, A., Levy, A., Holcberg, G., Wiznitzer, A., Mazor, M., & Sheiner, E. (2009) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2008.09.016 · Cited by 46 · cited 1×
“…vs. 1.6; Preeclampsia: 2.9 vs. 1.4; Labor induction: 1.2 vs. 0.3; gestational weight gain: 10.3 (3.4) vs. 8 (2.8); Primary cesarean section: 29.8 vs. 15.3 Karmon et al., 2009 Israel CC n = 10,227 n = 174,029 Hypertensive disorders: 11.6 vs. 5.5 Abruption: 0.8 vs. 0.7; Laborinduction: 42.1 vs. 27.0.”
InfluentialKgosidialwa, O., Egan, A. M., Carmody, L., Kirwan, B., Gunning, P., & Dunne, F. P. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3259 · Cited by 46 · cited 1×
“No GDM, not overweight Pre-eclampsia or eclampsia: 1.9 vs. 5.5 vs. 1.2; Labor induction: 42.1 vs. 58.4 vs. 28.5 Kgosidialwa et al., 2015 Ireland IADPSG n = 567, Age: 33.4 (4.9), BMI: 30.5 (6.1) n = 2499, Age: 31.5 (5.2), BMI: 26.7(4.8) Pre-eclampsia: 4.2 vs. 3.8; Hypertensive pregnancy disorders:…”
InfluentialAnsarzadeh, S., Salehi, L., Mahmoodi, Z., & Mohammadbeigi, A. (2020) · Health and Quality of Life Outcomes · doi:10.1186/s12955-020-01293-4 · Cited by 44
Gestational Diabetes Mellitus: Screening and Outcomes in Southern Italian Pregnant Women
Capula, C., Chiefari, E., Vero, A., Arcidiacono, B., Iiritano, S., Puccio, L., Pullano, V., Foti, D. P., Brunetti, A., & Vero, R. (2013) · ISRN Endocrinology · doi:10.1155/2013/387495 · Cited by 43 · cited 1×
“…GDMDiagnostic Criteria GDM Characteristics * Non-GDM Characteristics * Adverse Maternal Outcome in Women with vs. without GDM, % or Mean (SD) Capula et al., 2013 Italy IADPSG n = 171, Age: 30.8 (3.2), BMI: 22.8 (1.9) n = 367, Age: 29.3 (3.5), BMI: 21.4 (2.0) Hypertension: 4.1 vs. 1.6;…”
InfluentialFirst trimester prediction of maternal glycemic status
Gabbay‐Benziv, R., Doyle, L. E., Blitzer, M. G., & Baschat, A. (2014) · Journal of Perinatal Medicine · doi:10.1515/jpm-2014-0149 · Cited by 43
Anderberg, E., Källén, K., & Berntorp, K. E. (2010) · Acta Obstetricia Et Gynecologica Scandinavica · doi:10.3109/00016349.2010.526186 · Cited by 40 · cited 1×
“…6.9 vs. 4.2; Placenta Previa or abruption: 1.6 vs. 1.1; APH: 1.5 vs. 1.1; PPH: 6.3 vs. 6; Severe PPH: 0.9 vs. 0.7; Labor induction: 32.7 vs. 23.9 Anderberg et al., 2010 Sweden WHO-1999 n = 306, Age: 32 (18–46) n = 329, Age: 31 (20–42) Labor induction: 18.6 vs. 6.4 Avalos et al., 2013 Ireland…”
InfluentialKieffer, E. C., Tabaei, B. P., Carman, W. J., Nolan, G. H., Guzman, J. R., & Herman, W. H. (2006) · American Journal of Public Health · doi:10.2105/ajph.2005.065953 · Cited by 39 · cited 2×
“…2013 Canada CDA n = 15,404, Age: 31.5 (5.4) n = 407,268, Age: 28.4 (5.6) Preeclampsia/eclampsia: 2.6 vs. 1.2; Labor induction: 41.9 vs.27.1 Edith Kieffer et al., 2006 Mexico ADA-2003 n = 68, Age: 28.6 (0.6), BMI: 25.7 (0.2) n = 933, Age: 24.8 (0.2), BMI: 28.4 (0.8) Weight gain (kg): 10.0 (0.6)…”
InfluentialSoliman, A. T., Salama, H., Rifai, H. A., Sanctis, V. D., Al-Obaidly, S., Qubasi, M. A., & Olukade, T. O. (2018) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · doi:10.23750/abm.v89is4.7356 · Cited by 39
Hosseini, E., Janghorbani, M., & Shahshahan, Z. (2018) · Midwifery · doi:10.1016/j.midw.2018.07.017 · Cited by 39 · cited 3×
“Another meta-analysis by Hosseini et al. (2018) [15] assessed the magnitude of the association between GDM using the IADPSG or Carpenter and Coustan criteria and selected adverse perinatal events.”
MethodInfluentialCost-effectiveness analysis of gestational diabetes mellitus screening in France
Poncet, B., Touzet, S., Rocher, L., Berland, M., Orgiazzi, J., & Colin, C. (2002) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/s0301-2115(02)00042-8 · Cited by 38
Ekeroma, A. J., Chandran, G. S., McCowan, L. M. E., Ansell, D., Eagleton, C. L., & Kenealy, T. W. (2014) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/ajo.12267 · Cited by 37 · cited 3×
“It should be noted that 9 studies used more than one GDM classification [21,29,40,44, 47,51,53,59,64] as follows: 4 studies used classifications 1 and 5 [40,47,52,63], one used 1 and 2 classifications [59], one used classifications 1, 2 and 4 [51], one used classifications 1 and 7 [21], one used classifications 5 and…”
MethodInfluentialGlobal cost-effectiveness of GDM screening and management: Current knowledge and future needs
Weile, L. K. K., Kahn, J. G., Marseille, E. A., Jensen, D. M., Damm, P., & Lohse, N. (2014) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2014.06.009 · Cited by 35 · cited 1×
“Until now, there are not sufficient data to demonstrate the cost-effectiveness superiority of one screening and diagnostic approach over the other [75,76].”
BackgroundSugaya, A., Sugiyama, T., Nagata, M., & Toyoda, N. (2000) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(00)00135-2 · Cited by 34 · cited 2×
“It should be noted that 9 studies used more than one GDM classification [21,29,40,44, 47,51,53,59,64] as follows: 4 studies used classifications 1 and 5 [40,47,52,63], one used 1 and 2 classifications [59], one used classifications 1, 2 and 4 [51], one used classifications 1 and 7 [21], one used classifications 5 and…”
MethodInfluentialJacklin, P. B., Maresh, M. J., Patterson, C. C., Stanley, K. P., Dornhorst, A., Burman-Roy, S., & Bilous, R. W. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-016621 · Cited by 31 · cited 1×
“has been used as the first criteria for the definition of GDM; subsequently, GDM has been defined based on adverse pregnancy outcomes [11] after the Hyperglycemia and Adverse Pregnancy Outcomes’ (HAPO) study, which has shown a linear continuous association between the increasing values of maternal blood glucose and ad…”
MethodSon, K. H., Lim, N.-K., Lee, J. ‐., Cho, M. ‐., & Park, H. (2014) · Diabetic Medicine · doi:10.1111/dme.12656 · Cited by 30
Hosseini, E., Janghorbani, M., & Aminorroaya, A. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.04.014 · Cited by 30 · cited 4×
“Another meta-analysis by Hosseini et al. (2018) [15] assessed the magnitude of the association between GDM using the IADPSG or Carpenter and Coustan criteria and selected adverse perinatal events.”
MethodInfluentialvon Katterfeld, B., Li, J., McNamara, B. A., & Langridge, A. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03483.x · Cited by 30
Maternal gestational diabetes and long-term respiratory related hospitalizations of the offspring
Zamstein, O., Sheiner, E., Wainstock, T., Landau, D., & Walfisch, A. (2018) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2018.03.050 · Cited by 29 · cited 1×
“…(2) Weight gain: 12.50 (5.76) vs. 14.19 (5.71) Gortazar et al., 2018 Spain NDDG n = 35,729, Age: 33.42 n = 704,148, Age: 31.27 Pre-eclampsia: 2.56 vs. 1.44 Zamstein et al., 2018 Israel ACOG GDM A1: n = 9460, Age: 32.1 (5.8)GDM A2: n = 724, Age: 33.7 (5.6) n = 206,013, Age: 28 (5.7) GDM A1 vs.…”
InfluentialErjavec, K., Poljičanin, T., & Matijević, R. (2016) · Journal of Pregnancy · doi:10.1155/2016/2670912 · Cited by 28 · cited 3×
“9% studies were prospective or retrospective cohorts [22–68] and 4% were cross-sectional studies [20,21].”
BackgroundMethodInfluentialPan, L., Leng, J., Liu, G., Zhang, C., Liu, H., Li, M., Tan, L., Tian, H., Chan, J. C. N., Hu, G., et al. (2015) · Clinical Endocrinology · doi:10.1111/cen.12801 · Cited by 28 · cited 1×
“…27.6 (0.8) n = 2107, Age: 26.3 (0.1), BMI: 22.8(0.1) Pregnancy-induced hypertension: 3.8 vs. 3.7; Weight gain: 30.2 (1.8) (pounds) vs. 33.0 (0.3) Pan et al., 2015 China (1) WHO-1999(2) IADPSG (1) n = 257, Age: 29 (2.6), Prepregnancy BMI: 22.9 (3.5) (2) n = 429, Age: 28.8 (2.9), Prepregnancy…”
InfluentialAbnormal glucose tolerance later in life in women affected by glucose intolerance during pregnancy
Corrado, F., D’Anna, R., Laganà, A. S., & Benedetto, A. D. (2014) · Journal of Obstetrics and Gynaecology · doi:10.3109/01443615.2013.841658 · Cited by 27 · cited 1×
“However, GDM is strongly associated with a higher risk of adverse pregnancy outcomes [6,7], lifelong risk of abnormal glucose tolerance, and diabetes later in life [8,9].”
BackgroundGlucose Tolerance During Pregnancy and Birth Weight in a Hispanic Population
Kieffer, E. C., Nolan, G. H., Carman, W. J., Sanborn, C. Z., Guzmán, R., & Ventura, A. (1999) · Obstetrics and Gynecology · doi:10.1016/s0029-7844(99)00390-7 · Cited by 27 · cited 2×
“…HAPO 2–1: Hypertensive disorders of pregnancy: 9.6; Labor induction: 38.2 HAPO 2–2: Hypertensive disorders of pregnancy: 11.7; Labor induction: 42.3 Kieffer et al., 1999 Michigan NDDG n = 19, Age: 29.4 (6.2), BMI: 28.7 (5.7) n = 353, Age: 24.79 (4.85), BMI: 25.1(4.21) Hypertensive disorder:…”
MethodInfluentialMeinzer, C., Gebregziabher, M., Korte, J. E., MAULDIN, J. G., & Hunt, K. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065017 · Cited by 25 · cited 1×
“…28.4 (0.8) Weight gain (kg): 10.0 (0.6) vs. 13 (0.2) Goswami Mahanta et al., 2014 India DIPSI N = 28 n = 749 Gestational hypertension: 53.6 vs. 28.1 Ellerbe et al., 2013 USA ICD-9 Non-Hispanic White: n = 8567, Age: 29.6 (5.9), BMI: 29.3(7.3) Non-Hispanic Black n = 4724, Age: 27.5 (6.2), BMI: 31.7…”
InfluentialZeki, R., Oats, J. J. N., Wang, A. Y., Li, Z., Homer, C., & Sullivan, E. (2018) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.13605 · Cited by 25 · cited 1×
“…to week 28, GWG: 5.6 (3.9, 7.4) vs. 6.5 (4.7, 8.2) vs. 6.6 (6.0, 7.1), week 28 to birth, GWG: 5.1 (2.9, 7.4) vs. 4.8 (2.5, 7.0) vs. 5.2 (4.5, 5.9) Zeki et al., 2018 Australia ADIPS n = 51135, Age: 32.2 (5.3) n = 950 678, Age: 29.9 (5.6) Primary Cesarean: Relative % 13.8 vs. 13.5 Hoorn et al.,…”
InfluentialHosseini, E., & Janghorbani, M. (2018) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.12644 · Cited by 25
Gu, Y., Lü, J., Li, W., Liu, H., Wang, L., Leng, J., Li, W., Zhang, S., Wang, S., Tuomilehto, J. O., et al. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00645 · Cited by 24 · cited 2×
“It should be noted that 9 studies used more than one GDM classification [21,29,40,44, 47,51,53,59,64] as follows: 4 studies used classifications 1 and 5 [40,47,52,63], one used 1 and 2 classifications [59], one used classifications 1, 2 and 4 [51], one used classifications 1 and 7 [21], one used classifications 5 and…”
MethodInfluentialLamminpää, R., Vehviläinen-Julkunen, K. M., Gissler, M., Selander, T. A., & Heinonen, S. T. (2014) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.3109/14767058.2014.986450 · Cited by 23
Maternal and foetal outcome of gestational diabetes mellitus in a rural block of Assam, India
Mahanta, T. G., Deuri, A., Mahanta, B. N., Bordoloi, P., Rasaily, R., Mahanta, J., Baruah, S. D., & Gogoi, P. (2013) · Clinical Epidemiology and Global Health · doi:10.1016/j.cegh.2013.10.001 · Cited by 20 · cited 3×
“1%) group 3 [32,46, 56], 1 (2%) group 4 [51], 19 (38.”
InfluentialMorikawa, M., Sugiyama, T., Sagawa, N., Hiramatsu, Y., Ishikawa, H., Hamada, H., Kameda, T., Hara, E., Toda, S., & Minakami, H. (2017) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.13431 · Cited by 18
Davey, S., Jain, R. K., Davey, A., Raghav, S. K., & Singh, J. V. (2016) · Journal of Family and Community Medicine · doi:10.4103/2230-8229.181002 · Cited by 18 · cited 1×
“1%) group 3 [32,46, 56], 1 (2%) group 4 [51], 19 (38.”
Population-Level Outcomes with a 2-Step Approach for Gestational Diabetes Screening and Diagnosis
Donovan, L., Edwards, A. L., Savu, A., Butalia, S., Ryan, E. A., Johnson, J. A., & Kaul, P. (2017) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2016.12.010 · Cited by 17 · cited 2×
“It should be noted that 9 studies used more than one GDM classification [21,29,40,44, 47,51,53,59,64] as follows: 4 studies used classifications 1 and 5 [40,47,52,63], one used 1 and 2 classifications [59], one used classifications 1, 2 and 4 [51], one used classifications 1 and 7 [21], one used classifications 5 and…”
MethodInfluentialCan a Diagnosis of Gestational Diabetes Be an Advantage to the Outcome of Pregnancy?
Moses, R. G., & Griffiths, R. D. (1995) · Journal of the Society for Gynecologic Investigation · doi:10.1016/1071-5576(94)00060-e · Cited by 15
Kun, A. (2010) · Gynecologic and Obstetric Investigation · doi:10.1159/000320326 · Cited by 10
Renaming gestational diabetes mellitus: A psychosocial argument
Kalra, B., Gupta, Y., & Baruah, M. (2013) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.123539 · Cited by 9
Gestational diabetes: an onomastic opportunity
Kalra, S., Baruah, M. P., Gupta, Y., & Kalra, B. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70104-9 · Cited by 8 · cited 1×
“In addition, most available cost-effectiveness studies [75,77–80] were performed in developed societies with higher health economic resources and a lower rate of annual birth than developing and transitional countries [81].”
BackgroundGlucose Tolerance During Pregnancy and Birth Weight in a Hispanic Population
Kieffer, E. C., Nolan, G. H., Carman, W. J., Sanborn, C. Z., Guzmán, R., & Ventura, A. (1999) · Obstetrics and Gynecology · doi:10.1097/00006250-199911000-00019 · Cited by 8
Gestational diabetes mellitus screening, management and outcomes in the Cook Islands.
Aung, Y. Y. M., Sowter, M. C., Kenealy, T. W., Herman, J., & Ekeroma, A. J. (2015) · PubMed · Cited by 5
Diabetes and Pregnancy—An Endocrine Society Clinical Practice Guideline Publication Note
Lash, R. W. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01939 · Cited by 5
Research works printed but not linked: 2
- Higgins, J., and Green, S. (2011). Analysing data and undertaking meta-analyses In Cochrane Handbook for Systematic Reviews of Interventions (Version 5.1. 0), Wiley.
- ACOG (2018). Gestational Diabetes Mellitus, ACOG. ACOG Practice Bulletin.
Cited by
A global view of hypertensive disorders and diabetes mellitus during pregnancy
Jiang, L., Tang, K., Magee, L. A., von Dadelszen, P., Ekeroma, A., Li, X., Zhang, E., & Bhutta, Z. A. (2022) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00734-y · Cited by 314
Novel Biomolecules in the Pathogenesis of Gestational Diabetes Mellitus 2.0
Ruszała, M., Pilszyk, A., Niebrzydowska-Tatus, M., Kimber-Trojnar, Ż., Trojnar, M. P., & Leszczyńska‐Gorzelak, B. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084364 · Cited by 44
“Given the various diagnostic criteria and ethnicity, in many countries the epidemiology of GDM still remains unknown [8,9].”
BackgroundUpdate on gestational diabetes and adverse pregnancy outcomes
Ugwudike, B., & Kwok, M. H. (2023) · Current Opinion in Obstetrics & Gynecology · doi:10.1097/gco.0000000000000901 · Cited by 38
Tehrani, F. R., Naz, M. S. G., Yarandi, R. B., & Behboudi‐Gandevani, S. (2022) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2021.0178 · Cited by 37
“org GDM screening strategies classifications [99].”
Self-citationMahmoud, E., Elsayed, A. M., Elsayed, B. M. S., Elsalakawi, Y., Gopinath, A., & Chivese, T. (2024) · BMJ Open · doi:10.1136/bmjopen-2024-091258 · Cited by 34
Metadata
- Authors
- Ramezani Tehrani, F., Naz, M. S. G., Yarandi, R. B., & Behboudi-Gandevani, S.
- Affiliations
- Reproductive Endocrinology Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran 1985717413, Iran
- Research Institute for Endocrine Sciences (IR)
- Faculty of Nursing and Health Sciences, Nord University, 8049 Bodø, Norway
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2021-02-09
- Volume
- 10
- Issue
- 4
- Pages
- 666
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC7916110
- OpenAlex
- W3126866213
- Cited by
- 34
- References
- 83
- Citations by year
- 2026: 5 · 2025: 4 · 2024: 4 · 2023: 7 · 2022: 11 · 2021: 3
- FWCI
- 1.15
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- NORA - Norwegian Open Research Archives (submittedVersion, cc-by)
- Funders
- National Institutes for Medical Research Development (NIMAD) (972438)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Obstetrics and Gynecology › Pregnancy and preeclampsia studies
- Keywords
- gestational diabetes mellitus, diagnostic criteria, adverse maternal outcomes, IADPSG criteria, primary cesarean section, labor induction, maternal hemorrhage, pregnancy-related hypertension, universal screening, diagnostic thresholds, GDM prevalence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.